by Jeffrey Ventimiglia; Amir H. Kalali, MD; and Roger McIntyre, MD, FRCPC

Mr. Ventimiglia is an analyst in the Drug Safety and Medical Affairs Department, Quintiles, Inc., Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California; and Dr. McIntyre is Associate Professor of Psychiatry and Pharmacology, Head, Mood Disorders Psychopharmacology Unit, University of Toronto, Ontario, Canada.

Psychiatry (Edgemont) 2009;6(10):12–15